| News
Novartis works with Microsoft on artificial intelligence
02.10.2019
Novartis has selected Microsoft as its new strategic artificial intelligence (AI) and data science partner. With the collaboration, the Basel pharmaceutical giant aims to bolster its AI capacities and promote the development of transformative medicines.
Novartis Campus. (Img: Novartis)
Novartis has founded the Novartis AI Innovation Lab, announced a statement. In a strategic partnership, the Basel pharmaceutical company will work with Microsoft on research and development with two core objectives. Firstly, it will empower every Novartis employee to apply and use AI applications. Secondly, it will use AI to tackle existing challenges in life sciences.
To achieve these aims, Novartis and Microsoft will develop AI platforms to support future programs, while investing in projects, experts, technologies and tools. Novartis wants to continue evolving into a focused medicines company powered by advanced therapy platforms and data science, according to CEO Vas Narasimhan in the statement. “Pairing our deep knowledge of human biology and medicine with Microsoft’s leading expertise in AI could transform the way we discover and develop medicines for the world,” he said.
Satya Nadella, CEO of Microsoft, explained that the strategic alliance would address some of the biggest challenges facing the life sciences industry today and could help discover new medicines and reduce patient costs.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read More
KUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read More
Cell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read More
BLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read More
Combatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read More
AMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read More
Investors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read More
BSI integrating AI from Parashift in banking software
Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...
Read More
UptownBasel joins IBM Quantum Network
UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...
Read More
South Korean pharma firms show interest in the Basel Area
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...
Read More
